Evidence map›Paper›PMID 33448320›Full record

ReviewInternational journal of molecular medicine2021

Molecular mechanisms of astragaloside‑IV in cancer therapy (Review).

Tianqi Chen, Peiying Yang, Yingjie Jia

Open access · hybridAbstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in International journal of molecular medicine, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 41 papers, 4 of them syntheses that pooled it.

0numbers the graph read from it
0cells of the map it votes in
41citing papers in PubMed, 4 pooled it
16.6field-weighted citation impact, top 1% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

41 citing papers in PubMed, 4 syntheses or guidelines pooled it, 84 citations in OpenAlex.

  1. Pooled it
  2. Pooled it
  3. Pooled it
  4. Pooled it
  5. Article
  6. Article
  7. Article
  8. Article
  9. Article
  10. Review
  11. Article
  12. Article
  13. Review
  14. Review
  15. Review
  16. Article
  17. Article
  18. Review
  19. Article
  20. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Tianqi ChenDepartment of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300380, P.R. China.
Peiying YangDepartment of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300380, P.R. China.
Yingjie JiaDepartment of Oncology, First Teaching Hospital of Tianjin University of Traditional Chinese Medicine, Tianjin 300380, P.R. China.
First Teaching Hospital of Tianjin University of Traditional Chinese Medicine · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Radix Astragali (RA) is widely used in traditional Chinese medicine (TCM), and astragaloside IV (AS‑IV) is the most critical component of RA. Previous studies have demonstrated that AS‑IV exerts effects on the myocardium, nervous system and endocrine system, among others. In the present review article, data from studies conducted over the past 20 years were collated, which have evaluated the effects of AS‑IV on tumors. The mechanisms of action of AS‑IV on malignant cells both

Indexed as

NeoplasmsApoptosisHumansMAP Kinase Signaling SystemNeoplasm ProteinsSaponinsTriterpenesWnt Signaling Pathwayastragaloside ANeoplasm ProteinsSaponinsTriterpenesastragaloside IVcancerchemosensitivityepithelial‑mesenchymal transformationmolecular mechanisms

Identifiers

PMID33448320
PMCPMC7834967
OpenAlexW3119906275

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.